Updated Financial Calendar for 2022
Orphazyme A/S in restructuringCompany announcement No. 19/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, April…
News
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3…
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
New York, NY, and Tel Aviv, ISRAEL, April 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire —Todos…
Day One to Present at the 21st Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be…
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”),…
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022
Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the…
Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference
SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional…
Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader…
Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology…
Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…
Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation
ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc…
Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for…
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
Topline data anticipated in late Q3/early Q4 A total of 432 subjects are enrolled in…
Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq:…
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo…